Daniel J. Hicklin

C4 Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

103h-index52.8kcitations340works0.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(132), Cancer, Hypoxia, and Metabolism(59), Immune Cell Function and Interaction(52), CAR-T cell therapy research(50), Monoclonal and Polyclonal Antibodies Research(39)

Publications340 total

WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins

Cancer Immunology Research·2026

Supplemental Table 1 from mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2025Open Access

Supplemental Table 5 from mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2025Open Access

Supplemental Table 2 from mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2025Open Access

Supplemental Figures from mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2025Open Access

Supplemental Table 4 from mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2025Open Access

Supplemental Table 3 from mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2025Open Access

861 Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicity

Regular and Young Investigator Award Abstracts·2025Open Access

862 Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: Real-time assessment of tumor-specific activation and immune modulation

Regular and Young Investigator Award Abstracts·2025Open Access

964 Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity

Regular and Young Investigator Award Abstracts·2025Open Access

955 INDUKINE™ molecules delivering various cytokines utilize unique mechanisms of action to drive anti-tumor efficacy in murine syngeneic tumor models

Regular and Young Investigator Award Abstracts·2024Open Access

Supplemental Table 1 from mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2024Open Access

Supplemental Table 2 from mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2024Open Access

Supplemental Table 4 from mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2024Open Access

Supplemental Figures from mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2024Open Access

Supplemental Table 3 from mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2024Open Access

Data from mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2024Open Access

Supplemental Table 4 from mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2024Open Access

Supplemental Table 1 from mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2024Open Access

Supplemental Table 5 from mWTX-330, an IL 12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity

2024Open Access

page 1 of 17Next →

Frequent Co-authors

Peter Böhlen(12), Zhenping Zhu(10), Yan Wu(10), Larry Witte(10), Shahin Rafii(9), Lee M. Ellis(8), Robert S. Kerbel(8), Koichi Hattori(7), Sérgio Dias(7), Beate Heissig(7), David Lyden(6), Malcolm A.S. Moore(6), Shan Man(6), Neil R. Hackett(5), Ronald G. Crystal(5), Andrea T. Hooper(5), Peter Carmeliet(4), Lieve Moons(4), Mieke Dewerchin(4), Sergey V. Kozin(4)